<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37165299</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1970-9366</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Internal and emergency medicine</Title><ISOAbbreviation>Intern Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Bleeding and thrombotic events in a patient with lupus anticoagulant-associated hypoprothrombinemia and antiphospholipid antibody syndromes: managing hemostasis between Scylla and Charybdis.</ArticleTitle><Pagination><StartPage>1233</StartPage><EndPage>1238</EndPage><MedlinePgn>1233-1238</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11739-023-03292-x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipari</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamburini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>SOD Medicina Interna Interdisciplinare, AOU Careggi, Firenze, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castaman</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dipartimento di Oncologia, AOU Careggi, Centro di Malattie Emorragiche e Trombotiche, Firenze, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prisco</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>SOD Medicina Interna Interdisciplinare, AOU Careggi, Firenze, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Medicina Sperimentale e Clinica, Universit&#xe0; di Firenze, Firenze, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Candia</LastName><ForeName>Erica</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0942-2819</Identifier><AffiliationInfo><Affiliation>Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy. erica.decandia@unicatt.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Medicina e Chirurgia Traslazionale, Universita Cattolica del Sacro Cuore, Roma, Italy. erica.decandia@unicatt.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Intern Emerg Med</MedlineTA><NlmUniqueID>101263418</NlmUniqueID><ISSNLinking>1828-0447</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016682">Lupus Coagulation Inhibitor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C562724">Dysprothrombinemia</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016682" MajorTopicYN="N">Lupus Coagulation Inhibitor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007020" MajorTopicYN="Y">Hypoprothrombinemias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006487" MajorTopicYN="N">Hemostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37165299</ArticleId><ArticleId IdType="doi">10.1007/s11739-023-03292-x</ArticleId><ArticleId IdType="pii">10.1007/s11739-023-03292-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tektonidou MG et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296&#x2013;1304. https://doi.org/10.1136/annrheumdis-2019-215213</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Forastiero R (2012) Bleeding in the antiphospholipid syndrome. Hematology 17(SUPPL):1. https://doi.org/10.1179/102453312X13336169156654</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/102453312X13336169156654</ArticleId></ArticleIdList></Reference><Reference><Citation>Unlu O, Zuily S, Erkan D (2016) The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 3(2):75&#x2013;84. https://doi.org/10.5152/eurjrheum.2015.0085</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2015.0085</ArticleId><ArticleId IdType="pubmed">27708976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB (1983) A mechanism for the Hypoprothrombinemia of the acquired Hypoprothrombinemia-Lupus Anticoagulant syndrome. Blood 61(4):684&#x2013;692</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V61.4.684.684</ArticleId><ArticleId IdType="pubmed">6403077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapaport S, Ames S, Duvall BJ (1960) &#x201c;A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 15(2):212&#x2013;227</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V15.2.212.212</ArticleId><ArticleId IdType="pubmed">14436248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazodier K et al (2012) Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (United States) 91(5):251&#x2013;260. https://doi.org/10.1097/MD.0b013e31826b971f</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0b013e31826b971f</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulliez SMN et al (2015) Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature. Lupus 24(7):736&#x2013;745. https://doi.org/10.1177/0961203314558859</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314558859</ArticleId><ArticleId IdType="pubmed">25391540</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin Gedik K, Siddique S, Aguiar CL (2018) Rituximab use in pediatric lupus anticoagulant hypoprothrombinemia syndrome&#x2014;report of three cases and review of the literature. Lupus 27(7):1190&#x2013;1197. https://doi.org/10.1177/0961203317751853</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317751853</ArticleId><ArticleId IdType="pubmed">29320972</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilania RK et al (2018) &#x201c;Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature. Rheumatol Int 38(10):1933&#x2013;1940. https://doi.org/10.1007/s00296-018-4127-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-018-4127-9</ArticleId><ArticleId IdType="pubmed">30099593</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinet &#xc9;, Rich &#xc9;, Sen&#xe9;cal J-L (2006) Thromboembolism Complicating the Treatment of Lupus Anticoagulant Hypoprothrombinemia Syndrome. [Online]. Available: www.jrheum.org</Citation></Reference><Reference><Citation>Llorente-Ch&#xe1;vez A, Plascencia-F&#xe9;lix JF, Merayo-Chalico J (2021) Lupus anticoagulant-hypoprothrombinaemia syndrome: subdural haematoma as an unusual and initial manifestation. Mod Rheumatol Case Rep 5(2):306&#x2013;309. https://doi.org/10.1080/24725625.2021.1920139</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/24725625.2021.1920139</ArticleId><ArticleId IdType="pubmed">33970809</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R, Forastiero R, Pengo V, Lambert M, Martinez-Zamora MA, Balasch J, Zuily S, Wahl D, Amoura Z (2014) Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 13(3):281&#x2013;291. https://doi.org/10.1016/j.autrev.2013.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.10.014</ArticleId><ArticleId IdType="pubmed">24189281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bala MM, Paszek E, Lesniak W, Wloch-Kopec D, Jasinska K, Undas A (2018) Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012534.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012534.pub2</ArticleId><ArticleId IdType="pubmed">30141826</ArticleId><ArticleId IdType="pmc">6513478</ArticleId></ArticleIdList></Reference><Reference><Citation>Galland J et al (2016) Lupus anticoagulant-hypoprothrombinemia syndrome and catastrophic antiphospholipid syndrome in a patient with antidomain i antibodies. Blood Coag Fibrinol 27(5):580&#x2013;582. https://doi.org/10.1097/MBC.0000000000000545</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0000000000000545</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>